 | • レポートコード：MRC2301F0072 • 出版社/出版日：Transparency Market Research / 2022年10月3日 • レポート形態：英文、PDF、230ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスペアレンシー・マーケット・リサーチ社の当調査資料では、世界のマウスモデル作製市場について総合的に調査・分析を行い、序論、仮定・調査手法、市場概要、主要インサイト、技術別（CRISPRノックアウト、CRISPRノックイン、ランダム挿入、ラージ＆ターゲット挿入、その他）分析、エンドユーザー別（製薬企業、バイオテクノロジー企業、学術＆研究機関、研究＆製造受託機関）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東/アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、当市場の主要企業には、B BIOCYTOGEN、Charles River Laboratories、Cyagen Biosciences、Gempharmatech、genOway、ingenious targeting laboratory、Ozgene Pty Ltd.、Taconic Biosciences, Inc.、PolyGene AG、THE JACKSON LABORATORYなどが含まれています。 ・序論 ・仮定・調査手法 ・市場概要 ・主要インサイト ・世界のマウスモデル作製市場規模：技術別 - CRISPRノックアウト技術の市場規模 - CRISPRノックイン技術の市場規模 - ランダム挿入技術の市場規模 - ラージ＆ターゲット挿入技術の市場規模 - その他技術の市場規模 ・世界のマウスモデル作製市場規模：エンドユーザー別 - 製薬企業における市場規模 - バイオテクノロジー企業における市場規模 - 学術＆研究機関における市場規模 - 研究＆製造受託機関における市場規模 ・世界のマウスモデル作製市場規模：地域別 - 北米のマウスモデル作製市場規模 - 中南米のマウスモデル作製市場規模 - ヨーロッパのマウスモデル作製市場規模 - アジア太平洋のマウスモデル作製市場規模 - 中東/アフリカのマウスモデル作製市場規模 ・競争状況 ・企業情報 |
Mice Model Generation Market – Scope of Report
TMR’s report on the global mice model generation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global mice model generation market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mice model generation market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the mice model generation market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global mice model generation market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global mice model generation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global mice model generation market.
The report delves into the competitive landscape of the global mice model generation market. Key players operating in the global mice model generation market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global mice model generation market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market mice model generation.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Mice Model Generation Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Mice Model Generation Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Global Genetically Engineered Mouse Model Overview
5.2. Regulatory Scenario by Region/globally
5.3. Technological Advancements
5.4. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Mice Model Generation Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Technology, 2017–2031
6.3.1. CRISPR Knockout
6.3.2. CRISPR Knockin
6.3.3. Random Insertions
6.3.4. Large, Targeted Insertions
6.3.5. ES Cell Modification (homologous recombination)
6.3.6. Others
6.4. Market Attractiveness Analysis, by Technology
7. Global Mice Model Generation Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Pharmaceutical Companies
7.3.2. Biotechnology Companies
7.3.3. Academic & Research Facilities
7.3.4. Contract Research & Manufacturing Organizations
7.4. Market Attractiveness Analysis, by End-user
8. Global Mice Model Generation Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Mice Model Generation Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Technology, 2017–2031
9.2.1. CRISPR Knockout
9.2.2. CRISPR Knockin
9.2.3. Random Insertions
9.2.4. Large, Targeted Insertions
9.2.5. ES Cell Modification (homologous recombination)
9.2.6. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Pharmaceutical Companies
9.3.2. Biotechnology Companies
9.3.3. Academic & Research Facilities
9.3.4. Contract Research & Manufacturing Organizations
9.4. Market Value Forecast, by End-user by Technology, 2017–2031
9.4.1. Pharmaceutical Companies
9.4.1.1. CRISPR Knockout
9.4.1.2. CRISPR Knockin
9.4.1.3. Random Insertions
9.4.1.4. Large, Targeted Insertions
9.4.1.5. ES Cell Modification (homologous recombination)
9.4.1.6. Others
9.4.2. Biotechnology Companies
9.4.2.1. CRISPR Knockout
9.4.2.2. CRISPR Knockin
9.4.2.3. Random Insertions
9.4.2.4. Large, Targeted Insertions
9.4.2.5. ES Cell Modification (homologous recombination)
9.4.2.6. Others
9.4.3. Academic & Research Facilities
9.4.3.1. CRISPR Knockout
9.4.3.2. CRISPR Knockin
9.4.3.3. Random Insertions
9.4.3.4. Large, Targeted Insertions
9.4.3.5. ES Cell Modification (homologous recombination)
9.4.3.6. Others
9.4.4. Contract Research & Manufacturing Organizations
9.4.4.1. CRISPR Knockout
9.4.4.2. CRISPR Knockin
9.4.4.3. Random Insertions
9.4.4.4. Large, Targeted Insertions
9.4.4.5. ES Cell Modification (homologous recombination)
9.4.4.6. Others
9.5. Market Value Forecast, by Country, 2017–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Technology
9.6.2. By End-user
9.6.3. By End-user by Technology
9.6.4. By Country
10. Europe Mice Model Generation Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Technology, 2017–2031
10.2.1. CRISPR Knockout
10.2.2. CRISPR Knockin
10.2.3. Random Insertions
10.2.4. Large, Targeted Insertions
10.2.5. ES Cell Modification (homologous recombination)
10.2.6. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Pharmaceutical Companies
10.3.2. Biotechnology Companies
10.3.3. Academic & Research Facilities
10.3.4. Contract Research & Manufacturing Organizations
10.4. Market Value Forecast, by End-user by Technology, 2017–2031
10.4.1. Pharmaceutical Companies
10.4.1.1. CRISPR Knockout
10.4.1.2. CRISPR Knockin
10.4.1.3. Random Insertions
10.4.1.4. Large, Targeted Insertions
10.4.1.5. ES Cell Modification (homologous recombination)
10.4.1.6. Others
10.4.2. Biotechnology Companies
10.4.2.1. CRISPR Knockout
10.4.2.2. CRISPR Knockin
10.4.2.3. Random Insertions
10.4.2.4. Large, Targeted Insertions
10.4.2.5. ES Cell Modification (homologous recombination)
10.4.2.6. Others
10.4.3. Academic & Research Facilities
10.4.3.1. CRISPR Knockout
10.4.3.2. CRISPR Knockin
10.4.3.3. Random Insertions
10.4.3.4. Large, Targeted Insertions
10.4.3.5. ES Cell Modification (homologous recombination)
10.4.3.6. Others
10.4.4. Contract Research & Manufacturing Organizations
10.4.4.1. CRISPR Knockout
10.4.4.2. CRISPR Knockin
10.4.4.3. Random Insertions
10.4.4.4. Large, Targeted Insertions
10.4.4.5. ES Cell Modification (homologous recombination)
10.4.4.6. Others
10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Technology
10.6.2. By End-user
10.6.3. By End-user by Technology
10.6.4. By Country/Sub-region
11. Asia Pacific Mice Model Generation Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Technology, 2017–2031
11.2.1. CRISPR Knockout
11.2.2. CRISPR Knockin
11.2.3. Random Insertions
11.2.4. Large, Targeted Insertions
11.2.5. ES Cell Modification (homologous recombination)
11.2.6. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Pharmaceutical Companies
11.3.2. Biotechnology Companies
11.3.3. Academic & Research Facilities
11.3.4. Contract Research & Manufacturing Organizations
11.4. Market Value Forecast, by End-user by Technology, 2017–2031
11.4.1. Pharmaceutical Companies
11.4.1.1. CRISPR Knockout
11.4.1.2. CRISPR Knockin
11.4.1.3. Random Insertions
11.4.1.4. Large, Targeted Insertions
11.4.1.5. ES Cell Modification (homologous recombination)
11.4.1.6. Others
11.4.2. Biotechnology Companies
11.4.2.1. CRISPR Knockout
11.4.2.2. CRISPR Knockin
11.4.2.3. Random Insertions
11.4.2.4. Large, Targeted Insertions
11.4.2.5. ES Cell Modification (homologous recombination)
11.4.2.6. Others
11.4.3. Academic & Research Facilities
11.4.3.1. CRISPR Knockout
11.4.3.2. CRISPR Knockin
11.4.3.3. Random Insertions
11.4.3.4. Large, Targeted Insertions
11.4.3.5. ES Cell Modification (homologous recombination)
11.4.3.6. Others
11.4.4. Contract Research & Manufacturing Organizations
11.4.4.1. CRISPR Knockout
11.4.4.2. CRISPR Knockin
11.4.4.3. Random Insertions
11.4.4.4. Large, Targeted Insertions
11.4.4.5. ES Cell Modification (homologous recombination)
11.4.4.6. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Technology
11.6.2. By End-user
11.6.3. By End-user by Technology
11.6.4. By Country/Sub-region
12. Latin America Mice Model Generation Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Technology, 2017–2031
12.2.1. CRISPR Knockout
12.2.2. CRISPR Knockin
12.2.3. Random Insertions
12.2.4. Large, Targeted Insertions
12.2.5. ES Cell Modification (homologous recombination)
12.2.6. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Pharmaceutical Companies
12.3.2. Biotechnology Companies
12.3.3. Academic & Research Facilities
12.3.4. Contract Research & Manufacturing Organizations
12.4. Market Value Forecast, by End-user by Technology, 2017–2031
12.4.1. Pharmaceutical Companies
12.4.1.1. CRISPR Knockout
12.4.1.2. CRISPR Knockin
12.4.1.3. Random Insertions
12.4.1.4. Large, Targeted Insertions
12.4.1.5. ES Cell Modification (homologous recombination)
12.4.1.6. Others
12.4.2. Biotechnology Companies
12.4.2.1. CRISPR Knockout
12.4.2.2. CRISPR Knockin
12.4.2.3. Random Insertions
12.4.2.4. Large, Targeted Insertions
12.4.2.5. ES Cell Modification (homologous recombination)
12.4.2.6. Others
12.4.3. Academic & Research Facilities
12.4.3.1. CRISPR Knockout
12.4.3.2. CRISPR Knockin
12.4.3.3. Random Insertions
12.4.3.4. Large, Targeted Insertions
12.4.3.5. ES Cell Modification (homologous recombination)
12.4.3.6. Others
12.4.4. Contract Research & Manufacturing Organizations
12.4.4.1. CRISPR Knockout
12.4.4.2. CRISPR Knockin
12.4.4.3. Random Insertions
12.4.4.4. Large, Targeted Insertions
12.4.4.5. ES Cell Modification (homologous recombination)
12.4.4.6. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Technology
12.6.2. By End-user
12.6.3. By End-user by Technology
12.6.4. By Country/Sub-region
13. Middle East & Africa Mice Model Generation Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Technology, 2017–2031
13.2.1. CRISPR Knockout
13.2.2. CRISPR Knockin
13.2.3. Random Insertions
13.2.4. Large, Targeted Insertions
13.2.5. ES Cell Modification (homologous recombination)
13.2.6. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Pharmaceutical Companies
13.3.2. Biotechnology Companies
13.3.3. Academic & Research Facilities
13.3.4. Contract Research & Manufacturing Organizations
13.4. Market Value Forecast, by End-user by Technology, 2017–2031
13.4.1. Pharmaceutical Companies
13.4.1.1. CRISPR Knockout
13.4.1.2. CRISPR Knockin
13.4.1.3. Random Insertions
13.4.1.4. Large, Targeted Insertions
13.4.1.5. ES Cell Modification (homologous recombination)
13.4.1.6. Others
13.4.2. Biotechnology Companies
13.4.2.1. CRISPR Knockout
13.4.2.2. CRISPR Knockin
13.4.2.3. Random Insertions
13.4.2.4. Large, Targeted Insertions
13.4.2.5. ES Cell Modification (homologous recombination)
13.4.2.6. Others
13.4.3. Academic & Research Facilities
13.4.3.1. CRISPR Knockout
13.4.3.2. CRISPR Knockin
13.4.3.3. Random Insertions
13.4.3.4. Large, Targeted Insertions
13.4.3.5. ES Cell Modification (homologous recombination)
13.4.3.6. Others
13.4.4. Contract Research & Manufacturing Organizations
13.4.4.1. CRISPR Knockout
13.4.4.2. CRISPR Knockin
13.4.4.3. Random Insertions
13.4.4.4. Large, Targeted Insertions
13.4.4.5. ES Cell Modification (homologous recombination)
13.4.4.6. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Technology
13.6.2. By End-user
13.6.3. By End-user by Technology
13.6.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.2.1. Global
14.2.2. North America
14.2.3. Europe
14.2.4. By Asia Pacific
14.2.5. By Latin America
14.2.6. By Middle East & Africa
14.3. Company Profiles
14.3.1. Biocytogen
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Charles River Laboratories
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Cyagen Biosciences
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Gempharmatech
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. genOway
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. ingenious targeting laboratory
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Merck KGaA
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Ozgene Pty Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. Taconic Biosciences, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
14.3.10. PolyGene AG
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Strategic Overview
14.3.11. The Jackson Laboratory
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Strategic Overview
14.3.12. Yale School of Medicine
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Strategic Overview
14.3.13. University of North Carolina
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. SWOT Analysis
14.3.13.4. Strategic Overview
14.3.14. University of Nebraska Medical Center
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Product Portfolio
14.3.14.3. SWOT Analysis
14.3.14.4. Strategic Overview
14.3.15. Monash University
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Product Portfolio
14.3.15.3. SWOT Analysis
14.3.15.4. Strategic Overview
14.3.16. UMass Chan Medical School
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Product Portfolio
14.3.16.3. SWOT Analysis
14.3.16.4. Strategic Overview
14.3.17. University of Bonn
14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.17.2. Product Portfolio
14.3.17.3. SWOT Analysis
14.3.17.4. Strategic Overview
14.3.18. Columbia University
14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.18.2. Product Portfolio
14.3.18.3. SWOT Analysis
14.3.18.4. Strategic Overview
14.3.19. The University of Arizona
14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.19.2. Product Portfolio
14.3.19.3. SWOT Analysis
14.3.19.4. Strategic Overview
14.3.20. Hadassah BrainLabs
14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.20.2. Product Portfolio
14.3.20.3. SWOT Analysis
14.3.20.4. Strategic Overview
14.3.21. The Weizmann Institute of Science
14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.21.2. Product Portfolio
14.3.21.3. SWOT Analysis
14.3.21.4. Strategic Overview
14.3.22. The Hebrew University of Jerusalem
14.3.22.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.22.2. Product Portfolio
14.3.22.3. SWOT Analysis
14.3.22.4. Strategic Overview
14.3.23. The Technion – Israel Institute of Technology
14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.23.2. Product Portfolio
14.3.23.3. SWOT Analysis
14.3.23.4. Strategic Overview